Guardian Pharmacy Services, Inc. (GRDN)vsJohnson & Johnson (JNJ)
GRDN
Guardian Pharmacy Services, Inc.
$40.33
+1.95%
HEALTHCARE · Cap: $2.55B
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6688% more annual revenue ($99.33B vs $1.46B). JNJ leads profitability with a 16.2% profit margin vs 4.5%. JNJ trades at a lower P/E of 38.8x. JNJ earns a higher WallStSmart Score of 57/100 (C).
GRDN
Hold49
out of 100
Grade: D+
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GRDN.
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 139.8% YoY
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Trading at 10.4x book value
2.2% revenue growth
4.5% margin — thin
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : GRDN
The strongest argument for GRDN centers on EPS Growth, Altman Z-Score, Return on Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : GRDN
The primary concerns for GRDN are P/E Ratio, Price/Book, Revenue Growth. Thin 4.5% margins leave little buffer for downturns.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
GRDN profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 49/100), backed by strong 16.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Guardian Pharmacy Services, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, servicing assisted living and skilled nursing facilities. Known for its commitment to personalized medication management and stringent quality standards, the company leverages advanced technology and deep pharmaceutical expertise to enhance patient outcomes. With an extensive operational presence across multiple states, Guardian is well-positioned to address the growing demand for customized pharmacy services, ensuring optimal operational efficiency for its healthcare partners in an evolving market.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?